MARKET

KPRX

KPRX

KIORA PHARMACEUTICALS INC
NASDAQ
2.630
-0.030
-1.13%
After Hours: 2.630 0 0.00% 16:10 07/02 EDT
OPEN
2.680
PREV CLOSE
2.660
HIGH
2.740
LOW
2.620
VOLUME
8.96K
TURNOVER
--
52 WEEK HIGH
3.290
52 WEEK LOW
1.765
MARKET CAP
11.66M
P/E (TTM)
-0.9830
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at KPRX last week (0622-0626)?
Weekly Report · 5d ago
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Kiora Pharmaceuticals (KPRX) and MAIA Biotechnology, Inc. (MAIA)
TipRanks · 06/22 13:40
Weekly Report: what happened at KPRX last week (0615-0619)?
Weekly Report · 06/22 10:29
Analysts Are Bullish on Top Healthcare Stocks: Ascentage Pharma Group International (HK:6855), Kiora Pharmaceuticals (KPRX)
TipRanks · 06/20 09:01
Kiora Showcases Promising Preclinical Epilepsy Data for KIO-300
TipRanks · 06/18 11:41
Kiora Pharmaceuticals Released Preclinical Data Showing That KIO-300 Significantly Suppressed Seizure-associated Electrophysiological Activity In An Ex Vivo Temporal Lobe Epilepsy Model
Benzinga · 06/18 11:07
Kiora says KIO-300 suppresses seizure activity in preclinical epilepsy model
PUBT · 06/18 11:02
Weekly Report: what happened at KPRX last week (0608-0612)?
Weekly Report · 06/15 10:30
More
About KPRX
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). It is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.

Webull offers Kiora Pharmaceuticals Inc stock information, including NASDAQ: KPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KPRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KPRX stock methods without spending real money on the virtual paper trading platform.